
Financial engineering applied to funding biomedical research and drug development.
Princeton University Press. Listed on Lo's MIT books page.
Lo and Chaudhuri, working from Lo's research group at MIT, wrote this to apply financial engineering to the funding of biomedical research and drug development.
The problem they address is structural. Developing a drug takes over a decade, costs enormous sums, and fails most of the time, with success probabilities that vary by therapeutic area and by development stage. This risk profile does not suit any conventional funding source: venture capital funds have horizons shorter than the development cycle, public equity markets punish the volatility, and the probability of any single programme succeeding is too low for debt financing.
Their central proposal follows from portfolio theory. A single drug programme is unfinanceable because its failure probability is high and its outcome is binary. A portfolio of many independent programmes has a far more predictable aggregate outcome, because the failures and successes average, and a large enough portfolio can support debt financing that no individual programme could. They call this a megafund, and they model the required portfolio size, the capital structure combining debt and equity tranches, and the returns available to each. The essential requirement is statistical independence across programmes, which holds better across therapeutic areas than within one.
The book also covers the estimation of success probabilities from clinical trial databases, which is the input everything depends on and which the authors have worked to improve; adaptive trial design and its effect on cost and duration; the valuation of drug programmes as sequences of real options; patient preferences incorporated into regulatory decisions; and financing structures for rare diseases where the patient population cannot support conventional pricing.
The megafund proposal has attracted attention and limited implementation. Its dependence on statistical independence and on reliable success probability estimates is the practical constraint. The book is technical and assumes financial training.
Investors and operators in biotechnology and healthcare who want financial engineering applied to the funding structure of drug development.
Charles E. and Susan T. Harris Professor, MIT Sloan School of Management; Director, MIT Laboratory for Financial Engineering; founder of AlphaSimplex Group
The Econometrics of Financial Markets and the variance-ratio work with MacKinlay are primary sources the field builds on, and the Adaptive Markets Hypothesis is a named framework in its own right.
“Paper, September 2016. Lo, Andrew W., and Shomesh E. Chaudhuri, Healthcare Finance: Modern Financial Analysis for Accelerating Biomedical Innovation (Princeton, NJ: Princeton University Press, 2023)”
Chosen by shared topics, the entries that hold them, and the people who recommended both.
Research papers showing that stock prices do not follow a random walk.
“Andrew W. Lo and A. Craig MacKinlay, A Non-Random Walk Down Wall Street (Princeton, NJ: Princeton University Press, 1999), 4-5” — Michael Mauboussin
Source: Capital Ideas Revisited - Part 2: Thoughts on Beating a Mostly-Efficient Stock Market, page 9
Recommended by: Michael Mauboussin
The adaptive markets hypothesis, joining efficient markets and behavioural finance.
“Lo, Andrew W., Adaptive Markets: Financial Evolution at the Speed of Thought (Princeton, NJ: Princeton University Press, 2017)” — Michael Mauboussin
Source: Who Is On the Other Side? You Need Good BAIT to Land a Winner, page 40
Recommended by: Michael Mauboussin
Value is discounted future cash flow, not earnings per share or return on equity.
“Alfred Rappaport, a professor emeritus at the Kellogg School of Management at Northwestern University, made this point clearly in his seminal book, Creating Shareholder Value.” — Michael Mauboussin
Source: Market Share: Understanding Competitive Advantage Through Market Power, page 1
Recommended by: Michael Mauboussin, Mohnish Pabrai
Advanced valuation for the cases where the standard methods break down.
“We adapted this from Aswath Damodaran, Damodaran on Valuation (New York: John Wiley & Sons, 1994), 56-58” — Michael Mauboussin
Source: M&M on Valuation, page 13
Recommended by: Michael Mauboussin
Research on how hedge fund returns and risks behave, and how to measure them.
“Andrew W. Lo, Hedge Funds: An Analytic Perspective (Princeton, NJ: Princeton University Press, 2008), 255-302” — Michael Mauboussin
Source: Long-Term Investing: How I Learned to Stop Worrying and Ignore Volatility, page 6
Recommended by: Michael Mauboussin
Why a valuation needs both a business story and numbers, and how to join them.
“Aswath Damodaran, Narrative and Numbers: The Value of Stories in Business (New York: Columbia Business School Publishing, 2017)” — Michael Mauboussin
Source: Trading Stages in the Company Life Cycle, page 18
Recommended by: Michael Mauboussin